This biotech says it's already nailed down solid proof-of-concept data suggesting an objective response rate of 84% in an ongoing trial of lymphoma and leukemia patients being managed by the National Cancer Institute.
By tailoring these killer immune cells to express chimeric antigen receptors (CARs) or T cell receptors (TCRs), the biotech believes it can direct a personalized immune system attack on cancer cells, offering a new approach in immuno-oncology that has gripped much of the industry over the past two years.
Belldegrun also has the kind of pedigree that biotech investors tend to love. He co-founded the cancer drug developer Agensys, which was sold to Astellas 7 years ago for up to $537 million, and he chaired the scientific committee at Cougar, which triggered one of those high-profile billion-dollar buyout deals from Johnson & Johnson ($JNJ). The NCI's resident immuno-oncology specialist and melanoma expert, Steven Rosenberg, is directing much of the early-stage investigative work
According to the S-1, Kite has burned through $18.6 million to get to this point, a small sum in drug development circles. In turn, executives and directors at Kite have kept hold of 55% of the company's shares, and Belldegrun alone has managed to hang on to 22.5% of the equity.
Working with the NCI Natl Cancer Inst. You will see how this procedures actually alters your T and K cells in the body to self destruct all cancer that is there. I will state the only reason for the declines is Janet Yellen's comments. If you don't have the ball to ride a stock decline get out of the market totally. KITE needs to just make one simple announcement.
Stay long and strong.
CART is very very successful. The first one to successfully market it as a public company will be the first one to reap its benefits. Look at PCYC when it was in its infancy. GLTA
Seems like this has got to be illegal. Not to fair for those who are long. Shorts get the jump before his stories get published.
This whole new area for cancer treatment and using one's own T and K cells is going to make taking drugs obsolete for blood cancers.
Get in now and get 25% at least. GLTA
You won't be disappointed. Selloff won't be as big as these clown shorts say on the message board. GLTA.
Multiple Myeloma is a disease worse than CLL and AML. It create nodules and growths on the bone itself. Hard to treat let alone for any length of time. Treatment is mostly with Chemo.... aka Revlimid it works for a short time but most go to transplants cause treatment is shortlived. You can have an Autologous or Allogenic transplant. Most Multiple Myeloma patient have the severe form. Any treatment close to being successful border on miraculous. Although the study is small, one actually got a COMPLETE remission (unheard of) Lets see how this plays out. Buy on any pullback.
Treatment is far better option than a bone marrow transplant. This gives hope to those patients. This is unheard of with Multiple Myeloma. Awesome news.. congrats Karyopharm. The treck up will continue on Monday GLTA
The direction has been set now all that have to do is refine it and we are set to go over $100. 00 like PCYC. People don't get how big this really is. ONE complete remisssion is a big deal.
one complete response unheard of for Multiple Myeloma. 2 partials. 3 reduction in disease. I say this is a strong leap forward towards finding a solution for Multiple Myeloma. Those who don't follow treatment for this disease have no idea how big this is. GLTA news organizations will jump on this.
For those who sold great. For those who held you will be aptly rewarded. This has more room to run. Its recouping what was lost in biotech selloff in March. GLTA.
GLTA. Solution to cancer is found in finding the cures to blood cancers.
She is using her appendages again. Using them so much they are sore. She feels soreness and pain which is outstanding. Her breathing has improved. She even walks again with her walker. Outstanding. I believe April is getting benefits from being in the Neuralstem Clinical Trials.
CUR is for real. Now Adam says University Professors and Doctor's are full of it. Good Grief. bring on solid concrete negative news Adam or just shut up. I am holding long and strong. Don't give those people who have ALS any reason to not have HOPE bonehead.
let him do his due diligence. Whose shaking in there pants. NOT me. I just may even buy more when starts his far fetched stories. hahahhahaha